RNAi-based method of screening and characterizing drug combinations

Patent metadata

Field	Value
Publication number	US-9670486-B2
Application number	US-201113994057-A
Country	US
Kind code	B2
Filing date	Dec 16, 2011
Priority date	Dec 16, 2010
Publication date	Jun 6, 2017
Grant date	Jun 6, 2017

Abstract

In one aspect, the invention is directed to a method of characterizing a mechanism of action of a combination of agents. The method comprises contacting a plurality of populations of cells with a combination of agents to be assessed, wherein each population of cells have one gene of interest targeted by a small hairpin RNA (shRNA) and wherein the gene of interest regulates cell death and a plurality of genes that regulate cell death are targeted in the plurality of populations of cells. A responsiveness of each population of cells to the combination of agents is determined, thereby obtaining an shRNA signature of the combination of agents so as to identify one or more genes that mediate a response to the combination of agents, thereby characterizing the mechanism of action of the combination of agents. In another aspect, the invention is directed to a method of determining whether a patient population treated with a first agent would benefit from a treatment using the first agent in combination with one or more additional agents. In yet another aspect, the invention is directed to method of determining whether a formulation of one or more agents maintains a mechanism of action of the one or more agents when unformulated.

First claim

What is claimed is:

1. A method of characterizing a mechanism of action of a combination of agents comprising:
a) contacting each of eight populations of cells with a combination of agents to be assessed, wherein each population of cells expresses a small hairpin RNA (shRNA) that targets one of eight genes present in the cells, said eight genes consisting of p53, ATR, Chk1, Chk2, Smg-1, DNA-PKcs, Bok, and Bim genes; and
b) determining a responsiveness of each of the eight populations of cells to the combination of agents to obtain a combined shRNA signature of the combination of agents for the eight populations of cells, thereby characterizing the mechanism of action of the combination of agents.

2. The method of claim 1 wherein the mechanism of action indicates that the combination of agents has a neutralizing effect, a synergistic effect, a novel effect or a similar effect when compared to effects of individual agents of the combination.

3. The method of claim 1 wherein the mechanism of action of the combination of agents comprises inhibition of a topoisomerase, cross linking of DNA, inducement of single stand break of DNA, inhibition of nucleic acid synthesis, inhibition of mitosis, inhibition of RNA transcription, inhibition of histone modification enzymes, inhibition of heat shock proteins, alkylation of DNA, or inhibition of proteasomes inducement of apoptosis.

4. The method of claim 1 further comprising classifying the combination of agents within a group of one or more agents or a combination of agents having in common one or more mechanisms of action.

5. The method of claim 1 wherein each shRNA acts to knock down the gene that it targets.

6. The method of claim 1 wherein the combination of agents is used in an effective amount to induce a response in cells that do not contain shRNA targeting any of said eight genes.

7. The method of claim 1 wherein the cells are mammalian cells.

8. The method of claim 1 wherein the responsiveness of each of the populations of cells to the combination of agents is a relative level of chemo-resistance and sensitization conferred by each shRNA.

9. The method of claim 1 wherein the responsiveness of each of the populations of cells is a relative survival rate compared to control cells that do not contain shRNA targeting any of the eight genes.

10. The method of claim 1 wherein each of the populations of cells further expresses a marker gene.

11. The method of claim 1 wherein the shRNAs are introduced into the cells using a viral vector.

12. The method of claim 11 wherein the shRNAs are introduced into the cells using a retroviral vector.

13. The method of claim 11 wherein the vector further expresses a marker gene.

14. The method of claim 10 wherein the marker gene is a fluorescent marker gene.

15. The method of claim 10 wherein the marker gene is green fluorescent protein (GFP) gene.

16. The method of claim 14 further comprising measuring the fluorescent marker gene or GFP gene expression level in each of the populations of cells using cell flow cytometry.

17. The method of claim 1 further comprising comparing the responsiveness of each of the populations of cells to the combination of agents to a control.

18. The method of claim 17 wherein the control is a population of cells into which no shRNA targeting any of the eight genes has been introduced.

19. The method of claim 1 wherein the determination of the responsiveness is accomplished using cell flow cytometry, hybridization techniques or sequencing techniques.

20. The method of claim 1 wherein each of the populations of cells are contacted with the combination of agents for about 1 hour, 4 hours, 8 hours, 12 hours, 16 hours, 20 hours, 24 hours, 28 hours, 32 hours, 36 hours, 40 hours, 44 hours, 48 hours, 52 hours, 56 hours, 60 hours, 64 hours, 68 hours, 72 hours, 76 hours, 80 hours, 84 hours, 88 hours, 92 hours, 96 hours, 100 hours or longer.

21. The method of claim 1 wherein each of the populations of cells is contacted repeatedly with the combination of agents.

22. The method of claim 1 further comprising introducing the shRNAs into each of the populations of cells.

23. The method of claim 1 further comprising, using a processor, clustering representations of a plurality of combinations of agents into groups based on the responsiveness of each of the populations of cells to each combination of agents.

24. The method of claim 23 wherein clustering the representations of the plurality of the combinations of agents into groups includes:
determining an initial cluster size of a group of agents by determining an average of pairwise linkage distances among the group of agents, the group of agents formed based on the responsiveness of each of the populations of cells to each agent of the group;
predicting whether the agent belongs to the group using a probabilistic nearest neighbor calculation between the agent and the group of agents; and
if the agent is predicted to belong to the group, adding the agent to the group and determining a new cluster size for the group of agents, and determining a linkage ratio for the agent and the group of agents based on the initial cluster size and the new cluster size.

25. The method of claim 24 further comprising generating a background distribution of false linkage ratios by iteratively forcing out-of-group agents to belong to the group of agents.

26. The method of claim 25 wherein the background distribution indicates how unrelated agents affect cluster size.

27. The method of claim 25 further comprising comparing the new cluster size for the group of agents to the background distribution.

Assignees

• Pritchard Justin
• Lauffenburger Douglas A
• Hemann Michael
• Massachusetts Inst Technology

Inventors

• Pritchard Justin
• Lauffenburger Douglas A
• Hemann Michael

Classifications

• C12Q2600/178

  miRNA, siRNA or ncRNA · CPC title

• C12Q1/6883

  for diseases caused by alterations of genetic material · CPC title

• G01N33/5023

  on expression patterns · CPC title

• C12Q2600/136

  Screening for pharmacological compounds · CPC title

• C12N15/1079 Primary

  Screening libraries by altering the phenotype or phenotypic trait of the host (reporter assays C12N15/1086) · CPC title